• Anlotinib Inhibits Angiogenesis via Three Kinases

  2026-09-29

  The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1, with downstream attenuation of ERK signaling. Its combination of endothelial migration, tube formation, ex vivo vessel sprouting, and CAM assays provides a useful mechanistic framework for evaluating multi-target anti-angiogenic compounds.

• Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation

  2026-09-28

  Chavali and colleagues developed a chemically defined differentiation strategy that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells (RGCs) from induced pluripotent stem cells (iPSCs) with improved yield and reproducibility. The approach produced RGC-enriched populations without genetic modification and incorporated Thy-1-based magnetic purification, providing a practical platform for glaucoma modeling and regenerative-ophthalmology research.

• Temafloxacin Pharmacokinetics: Evidence and Implications

  2026-09-28

  This 1991 review integrates oral and intravenous temafloxacin data to explain its high bioavailability, prolonged elimination half-life, tissue distribution, and predominantly renal excretion. Its main contribution is a practical pharmacokinetic framework for interpreting dosing intervals and renal-function effects, while its findings remain specific to temafloxacin and the clinical evidence available at the time.

• Citron OGD2 Links Iron Uptake to Canker Resistance

  2026-09-27

  The study identifies CmOGD2 as a contributor to citron resistance against citrus canker, linking iron acquisition and reactive oxygen species to a likely ferroptosis-related defense response. It also describes a regulatory circuit in which CmENO2 limits CmOGD2 expression through CmZAT10.1, while the Xanthomonas effector pthA4 appears to disrupt that restraint.

• Thiazovivin (A5506) for Stem Cell Workflows

  2026-09-26

  Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming and human embryonic stem cell survival after trypsinization. This guide covers preparation and workflow controls; the dossier does not provide a cell-treatment dose, and the compound is for research use only—not diagnostic, clinical, or therapeutic use.

• (R)-MG132: A Control for Proteasome Validation

  2026-09-25

  (R)-MG132 provides a stereochemical negative-control arm for testing whether a protein-abundance change depends on proteasome inhibition. In cervical cancer metabolism studies, it can help separate proteasome-related effects from changes in HNRNPU lactylation, PHGDH expression, and serine-pathway regulation.

• Proteoform-Specific Drug Binding in Native Membranes

  2026-09-25

  Lutomski and colleagues present a native mass-spectrometry workflow that releases proteins and signaling complexes directly from retinal rod-disc membranes, preserving information about proteoforms and their interactions. The study links lipid modifications to G-protein assembly and shows that vardenafil and sildenafil have differential off-target interactions with retinal PDE6, illustrating why drug binding should be assessed in native membrane contexts.

• PDGF-BB in Pulmonary Hypertension: From Mitogen to Model

  2026-09-24

  A mechanistic perspective on using murine recombinant PDGF-BB to establish controlled proliferation assays alongside emerging research into metabolic remodeling in pulmonary hypertension.

• Deferiprone Workflows for Iron-Stress Research

  2026-09-24

  Use Deferiprone to create controlled iron-limitation models and track the resulting metabolic, inflammatory, and cell-fate responses. This guide translates enterocyte findings into practical assay choices while distinguishing established observations from research applications that require independent validation.

• Ibrutinib (PCI-32765): BTK Research Guide

  2026-09-23

  Ibrutinib, also called PCI-32765, is an irreversible BTK inhibitor for research on B-cell receptor signaling and B-cell biology. The product dossier reports a BTK IC50 of 0.5 nM and describes in vitro CLL effects, while emphasizing that assay conditions and clinical use are outside the product’s research scope.

• Firefly Luciferase mRNA: ARCA and 5-moUTP Guide

  2026-09-23

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is a modified, capped reporter transcript for luciferase-based gene expression, cell viability, and imaging workflows. This guide separates product specifications from peer-reviewed evidence and defines practical limits for interpreting bioluminescent signals.

• Telatinib Workflow for Angiogenesis Research

  2026-09-22

  Build a phenotype-centered workflow around Telatinib (BAY 57-9352) for endothelial tube formation, tumor-cell proliferation, and invasion studies. This guide emphasizes dose calibration, target attribution, DMSO control, and combination-assay design so antiangiogenic effects are not mistaken for nonspecific cytotoxicity.

• MIR9 Epigenetic Silencing in Acute Lymphoblastic Leukaemia

  2026-09-22

  The reference study links MIR9-family hypermethylation with reduced miR-9 expression, increased FGFR1 and CDK6 activity, and adverse outcomes in acute lymphoblastic leukaemia. Its combined clinical, epigenetic, and pharmacological evidence supports MIR9-regulated FGFR1 and CDK6 pathways as mechanistic and therapeutic research targets, while not establishing clinical efficacy for either inhibitor.

• Cabozantinib Adaptation in Renal Cell Carcinoma

  2026-09-21

  This 2026 study uses quantitative phosphoproteomics to show that acute and chronic Cabozantinib exposure produce distinct signaling states in renal cell carcinoma rather than a simple extension of the initial drug response. Persistent suppression of MET activation-loop phosphorylation coexisted with chronic adhesion-, stress-, and MAPK/AP-1-associated remodeling and modest, context-dependent motility changes.

• Cabozantinib: Temporal Signaling in RCC Models

  2026-09-21

  Cabozantinib research is moving beyond single-time-point potency measurements. This article explains how acute versus chronic exposure reshapes RCC phosphorylation networks and translates those findings into more discriminating assay decisions.

7449 records 1/497 page Next 12345 下5页 Last page